Ingredients | Amount Per Serving |
---|---|
FRAC(R)
(from Rice)
(FRAC(R) (Form: from rice) )
|
50 mg |
(from Rice)
(Gamma oryzanol (Form: from rice) )
|
25 mg |
Cellulose, Vegetable culture Note: specially grown, biologically active containing naturally associated and/or organically bound phytochemicals including polyphenolic compounds with superoxide dismutase and catalase, dehydrated at low temperature to preserve associated enzyme factors, Magnesium Stearate Note: vegetable source, Silica, Stearic Acid (Alt. Name: C18:0), modified Cellulose Gum
Below is general information about the effectiveness of the known ingredients contained in the product Gammanol Forte. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
Below is general information about the safety of the known ingredients contained in the product Gammanol Forte. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
POSSIBLY SAFE ...when used orally and appropriately. Gamma-oryzanol 300 mg daily has been used most commonly in clinical research without reports of adverse events (751,752,753,754,755,51111). ...when used topically and appropriately (51112).
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
Below is general information about the interactions of the known ingredients contained in the product Gammanol Forte. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Below is general information about the adverse effects of the known ingredients contained in the product Gammanol Forte. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General ...Gamma-oryzanol is generally well tolerated. No adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.